ChartMill assigns a Buy % Consensus number of 80% to CRVO. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-11 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-11-05 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2025-11-04 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-09-08 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2025-08-18 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-08-12 | Roth Capital | Reiterate | Buy -> Buy |
| 2025-08-11 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-08-11 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-07-29 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-07-28 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-07-25 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-06-11 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-05-13 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-05-12 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-26 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-03-18 | Roth MKM | Maintains | Buy -> Buy |
| 2025-03-18 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-18 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-03-17 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-03-13 | Jones Trading | Upgrade | Hold -> Buy |
| 2025-03-13 | Chardan Capital | Upgrade | Neutral -> Buy |
| 2025-03-11 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-03-11 | Roth MKM | Maintains | Buy -> Buy |
| 2025-02-19 | D. Boral Capital | Upgrade | Hold -> Buy |
| 2024-12-17 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-12-11 | Chardan Capital | Downgrade | Buy -> Neutral |
| 2024-12-11 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-12-10 | D. Boral Capital | Downgrade | Buy -> Hold |
| 2024-12-10 | Jones Trading | Downgrade | Buy -> Hold |
| 2024-12-05 | Roth MKM | Initiate | Buy |
13 analysts have analysed CRVO and the average price target is 22.88 USD. This implies a price increase of 130.15% is expected in the next year compared to the current price of 9.94.
The consensus rating for CERVOMED INC (CRVO) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.